In this article, we will discuss Goserelin (Mechanism of Action). So, let’s get started.
Mechanism of Action
Goserelin is a synthetic decapeptide analogue of GnRH. Goserelin acts as an inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. In animal and in vitro studies, administration of goserelin resulted in the regression or inhibition of growth of the hormonally sensitive dimethylbenzanthracene (DMBA)-induced rat mammary tumor and Dunning R3327 prostate tumor.
Pharmacodynamics
Following initial administration, Goserelin causes an initial increase in serum luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels with subsequent increases in serum levels of testosterone. Chronic administration of Goserelin leads to sustained suppression of pituitary gonadotropins, and serum
levels of testosterone consequently fall into the range normally seen in surgically castrated men approximately 21 days after initiation of therapy. This leads to accessory sex organ regression. In clinical trials using Goserelin 3.6 mg with follow-up of more than 2 years, suppression of serum testosterone to castrate levels has been maintained for the duration of therapy.